title: 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification.
abstract: OBJECTIVE
  The purpose of this study is to assess jailing of side branches (SB) by the everolimus-eluting, bioresorbable vascular scaffold (BVS) with 3-dimensional (3D) optical coherence tomography (OCT) reconstruction.
  
  
  BACKGROUND
  Because BVS struts at the SB orifice are suspected of being bioresorbed and/or forming a neointimal bridge, OCT has been used to evaluate the struts in detail at that particular site. Our understanding of the 3D relationship of the strut and the SB orifice is limited by the use of 2-dimensional OCT images. Fourier-domain OCT enables reliable 3D reconstruction of coronary vessels.
  
  
  METHODS
  The ABSORB Cohort B (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions) trial is a multicenter single-arm trial to assess the safety and performance of the BVS. Fourier-domain OCT pullbacks (C7-XR system, LightLab Imaging Inc., Westford, Massachusetts) are obtained at pullback speed of 20 mm/s and 3D renderings are performed. The orifices of the SB are assessed visually. The area of SB orifice and the number of strut-free compartments delineated by the BVS struts are evaluated.
  
  
  RESULTS
  Fifty-one OCT pullbacks were acquired: 33 pullbacks were imaged with Fourier-domain OCT and 27 treated segments had 46 side branches. Three-dimensional assessment was feasible in 87% (40 of 46) of pullbacks. The mean area of the SB orifice was 1.16 +/- 1.02 mm(2). The mean number of strut-free compartments was 2.0 +/- 1.1. The classification of the overhanging struts is proposed.
  
  
  CONCLUSIONS
  This study demonstrates that 3D OCT reconstruction is feasible to evaluate the orifices of SB jailed with BVS. (ABSORB Clinical Investigation, Cohort B; NCT00856856).
authors: Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
authors: Takayuki
authors: T
authors: Okamura
authors: Yoshinobu
authors: Y
authors: Onuma
authors: Héctor M
authors: HM
authors: García-García
authors: Evelyn
authors: E
authors: Regar
authors: Joanna J
authors: JJ
authors: Wykrzykowska
authors: Jacques
authors: J
authors: Koolen
authors: Leif
authors: L
authors: Thuesen
authors: Stefan
authors: S
authors: Windecker
authors: Robert
authors: R
authors: Whitbourn
authors: Dougal R
authors: DR
authors: McClean
authors: John A
authors: JA
authors: Ormiston
authors: Patrick W
authors: PW
authors: Serruys
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D001315:Australia; D002317:Cardiovascular Agents / Q000008:administration & dosage; D023921:Coronary Stenosis / Q000473:pathology / Q000628:therapy*; D054855:Drug-Eluting Stents; D005060:Europe; D000068338:Everolimus; D005240:Feasibility Studies; D005260:Female; D005583:Fourier Analysis; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D021621:Imaging, Three-Dimensional; D008297:Male; D008875:Middle Aged; D009520:New Zealand; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D009626:Terminology as Topic; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; D020123:Sirolimus